Evidence map›Paper›PMID 38022522›Full record

ArticleFrontiers in immunology2023

Detection of anti-SARS-CoV-2 salivary antibodies in vaccinated adults.

Vitória Tavares Castro, Hélène Chardin, Juliana Amorim Dos Santos, Gustavo Barcelos Barra, Grazielle Rodrigues Castilho, Paula Monteiro Souza, Pérola de Oliveira Magalhães, Ana Carolina Acevedo, Eliete Neves Silva Guerra

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Vitória Tavares CastroLaboratory of Oral Histopathology, Faculty of Health Sciences, University of Brasilia, Brasília, DF, Brazil.
Hélène ChardinDepartment of Analytical, Bioanalytical Sciences and Miniaturization, École Supérieure de Physique et de Chimie Industrielles (ESPCI) de la Ville de Paris, Paris, France.
Juliana Amorim Dos SantosLaboratory of Oral Histopathology, Faculty of Health Sciences, University of Brasilia, Brasília, DF, Brazil.
Gustavo Barcelos BarraSabin Medicina Diagnostica Laboratory, Institute Sabin, Brasília, DF, Brazil.
Grazielle Rodrigues CastilhoSabin Medicina Diagnostica Laboratory, Institute Sabin, Brasília, DF, Brazil.
Paula Monteiro SouzaLaboratory of Natural Products, Faculty of Health Sciences, University of Brasilia, Brasília, DF, Brazil.
Pérola de Oliveira MagalhãesLaboratory of Natural Products, Faculty of Health Sciences, University of Brasilia, Brasília, DF, Brazil.
Ana Carolina AcevedoLaboratory of Oral Histopathology, Faculty of Health Sciences, University of Brasilia, Brasília, DF, Brazil.
Eliete Neves Silva GuerraLaboratory of Oral Histopathology, Faculty of Health Sciences, University of Brasilia, Brasília, DF, Brazil.
Universidade de Brasília · BRSabin Medicina Diagnostica (Brazil) · BRESPCI Paris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the introduction of efficient anti-SARS-CoV-2 vaccines, the detection of antibodies becomes useful for immunological monitoring and COVID-19 control. Therefore, this longitudinal study aimed to evaluate the detection of SARS-CoV-2 antibodies in the serum and saliva of COVID-19-vaccinated adults. The study included 13 not vaccinated and 35 vaccinated participants with two doses of CoronaVac (Sinovac/Butantan) vaccine who subsequently received BNT162b2 (Pfizer-BioNTech) vaccine as a booster dose. Vaccinated participants donated saliva and serum in three different time points. Enzyme-linked immunosorbent assay was used for antibody detection. In our results, the serum neutralizing antibodies (NAb) were detected in 34/35 samples after second dose and in 35/35 samples one and five months after the booster dose. In saliva, NAb were detected in 30/35 samples after second dose and in 35/35 of samples one and five months after the booster dose. IgA was detected in 19/34 saliva samples after second dose, in 18/35 one month after the booster and in 30/35 five months after. IgG in saliva was detected in 1/34 samples after second dose, 33/35 samples one month after the booster dose and in 20/35 five months after. A strong correlation was found between IgG and neutralizing activity in saliva, and salivary IgA would be a sign of recent exposure to the virus. In conclusion, saliva can be suitable for monitoring antibodies anti-SARS-CoV-2 after vaccination. Heterologous vaccination contributed to increase anti-SARS-CoV-2 antibodies in the Brazilian health context. Complementary studies with large groups are mandatory to conclude the interest in following mucosal immunity.

Indexed as

BNT162 VaccineCOVID-19AdultAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansImmunoglobulin AImmunoglobulin GLongitudinal StudiesSARS-CoV-2Vaccines, InactivatedAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesImmunoglobulin AImmunoglobulin Gsinovac COVID-19 vaccineVaccines, InactivatedantibodiesCOVID-19COVID-19 vaccinesIgAIgGneutralizing antibodiessalivaSARS-CoV-2

Identifiers

PMID38022522
PMCPMC10661372
OpenAlexW4388456651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.